September 5, 2017 / 11:31 AM / a year ago

BRIEF-Insmed announces positive top-line results from phase 3 convert study of ALIS

Sept 5 (Reuters) - Insmed Inc

* Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC)

* Study met primary endpoint of culture conversion (p< 0.0001)​

* Positive top-line results from global phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection​

* Company plans to pursue accelerated approval and request priority review​

* Plans to pursue accelerated approval of ALIS under subpart H based on data from convert study, which will be reviewed by division of anti-infective products​

* Company also reported top-line data for several secondary endpoints as of 6-month timepoint​

* Top-line data for 6-minute walk test indicates no statistically significant difference between patients in two arms​

* Company is continuing its analysis of impact of conversion on a variety of other clinical measures​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below